PMID- 30535441
OWN - NLM
STAT- MEDLINE
DCOM- 20190131
LR  - 20200225
IS  - 1791-2431 (Electronic)
IS  - 1021-335X (Print)
IS  - 1021-335X (Linking)
VI  - 41
IP  - 2
DP  - 2019 Feb
TI  - lincRNA‑p21 inhibits the progression of non‑small cell lung cancer via targeting 
      miR‑17‑5p.
PG  - 789-800
LID - 10.3892/or.2018.6900 [doi]
AB  - Non‑small‑cell lung cancer (NSCLC) is well established as one of the major 
      subtypes of human lung cancer. NSCLC is characterized by a high incidence rate 
      and poor patient prognosis. Previous studies have identified that long intergenic 
      non-coding RNA (lincRNA) serves a key role in the development of tumor and 
      malignant metastasis. However, the majority of the underlying mechanisms for 
      lincRNA deregulation in various diseases, including cancer and diabetes, have not 
      been completely elucidated. In the present study, the deregulation of lincRNA‑p21 
      in NSCLC tumor tissues in comparison to adjacent healthy tissues was examined 
      using reverse transcription‑quantitative polymerase chain reaction. Furthermore, 
      the effect of lincRNA‑p21 overexpression and knockdown on different NSCLC cell 
      lines was further investigated in vitro. The association between lincRNA‑p21 
      expression and microRNA (miR)‑17‑5p level in NSCLC tumor cells was also 
      investigated to clarify the underlying mechanism. The influence of miR‑17‑5p on 
      different NSCLC cell lines A549 and PC9 were also examined in vitro using 
      miR‑17‑5p mimics and inhibitors. Bioinformatics and luciferase assays were 
      conducted to verify the direct binding sites on lincRNA‑p21 for miR‑17‑5p. The 
      results demonstrated that there was a significant low‑expression of lincRNA‑p21 
      in NSCLC tumor tissues, and lincRNA‑p21 effectively inhibited the progression of 
      lung cancer cells by suppressing cell proliferation and migration and promoting 
      cell apoptosis. An evident negative association between lincRNA‑p21 and miR‑17‑5p 
      expression was observed, and the inhibitory effect of overexpressed lincRNA‑p21 
      on lung cancer cells was counteracted by miR‑17‑5p. Bioinformatics and luciferase 
      reporter analysis results confirmed that miR‑17‑5p is a direct target for 
      lincRNA‑p21. The present study provides evidence for lincRNA‑p21 to inhibit the 
      progression of NSCLC via direct targeting of a miR‑17‑5p associated signaling 
      pathway.
FAU - Ao, Xiang
AU  - Ao X
AD  - The Second Clinical Medical College, Southern Medical University, Guangzhou, 
      Guangdong 510515, P.R. China.
FAU - Jiang, Ming
AU  - Jiang M
AD  - Thoracic Surgery Department, Affiliated Cancer Hospital and Institute of 
      Guangzhou Medical University, Guangzhou, Guangdong 510095, P.R. China.
FAU - Zhou, Jie
AU  - Zhou J
AD  - Thoracic Surgery Department, Affiliated Cancer Hospital and Institute of 
      Guangzhou Medical University, Guangzhou, Guangdong 510095, P.R. China.
FAU - Liang, Hongling
AU  - Liang H
AD  - Thoracic Surgery Department, Affiliated Cancer Hospital and Institute of 
      Guangzhou Medical University, Guangzhou, Guangdong 510095, P.R. China.
FAU - Xia, Haoming
AU  - Xia H
AD  - Thoracic Surgery Department, Affiliated Cancer Hospital and Institute of 
      Guangzhou Medical University, Guangzhou, Guangdong 510095, P.R. China.
FAU - Chen, Gang
AU  - Chen G
AD  - The Second Clinical Medical College, Southern Medical University, Guangzhou, 
      Guangdong 510515, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20181130
PL  - Greece
TA  - Oncol Rep
JT  - Oncology reports
JID - 9422756
RN  - 0 (MIRN17 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (RNA, Long Noncoding)
SB  - IM
MH  - A549 Cells
MH  - Adult
MH  - Animals
MH  - Carcinoma, Non-Small-Cell Lung/*genetics/pathology
MH  - Cell Proliferation/genetics
MH  - Computational Biology
MH  - Disease Progression
MH  - Down-Regulation
MH  - Female
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Lung/pathology
MH  - Lung Neoplasms/*genetics/pathology
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - MicroRNAs/*genetics
MH  - RNA, Long Noncoding/genetics/*metabolism
MH  - Xenograft Model Antitumor Assays
PMC - PMC6312999
EDAT- 2018/12/12 06:00
MHDA- 2019/02/01 06:00
PMCR- 2018/11/30
CRDT- 2018/12/12 06:00
PHST- 2018/03/25 00:00 [received]
PHST- 2018/10/26 00:00 [accepted]
PHST- 2018/12/12 06:00 [pubmed]
PHST- 2019/02/01 06:00 [medline]
PHST- 2018/12/12 06:00 [entrez]
PHST- 2018/11/30 00:00 [pmc-release]
AID - or-41-02-0789 [pii]
AID - 10.3892/or.2018.6900 [doi]
PST - ppublish
SO  - Oncol Rep. 2019 Feb;41(2):789-800. doi: 10.3892/or.2018.6900. Epub 2018 Nov 30.